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1. Introduction 
Duchenne muscular dystrophy is inherited as a 
sex-linked recessive trait. The primary cause of the 
disease is unknown, but several hypotheses xist, 
suggesting myopathic [1], neuronal [2], vascular [3], 
and auto-immune [4] mechanisms. Evidence in favour 
of abnormal functioning of cellular membranes has 
been put forward and also that this membrane defect 
may be generalized [5-7]. Several reports about 
structural alterations of membranes [8-10], altera- 
tions of different membrane enzymes [11-13], and 
other membrane proteins [13-15] have appeared. 
Elevated levels of muscle enzyme activities (e.g., 
creatine kinase in serum) and their depletion in the 
muscle tissue reflect a leakage in the muscle-cell mem- 
brane. 
Urinary excretion of various peptides in Duchenne 
muscular dystrophy was described in [16]. It was also 
observed that some of these peptide fractions differed 
in their ability to affect he growth of chick embryo- 
muscle fibroblasts in culture as compared with similar 
fractions from urine of normal individuals [16,17]. 
Urinary oligosaccharide excretion has been studied 
under different physiological conditions and in patients 
with various diseases [18]. It was recently reported 
that urine of a patient with glycogen-storage disease 
type II (Pompe's disease) had a dramatically increased 
excretion of a glucose-containing tetrasaccharide 
(89.6 rag/24 h urine) [19,20]: a-D-Glc-(I~6)-a-D-Glc- 
(I~4)-a-D-Glc-(1--~4)-D-Glc4, referred to here as 
(GIc)4. 
This oligosaccharide, which has been regarded as a 
'limit' oligosaccharide in the extracellular b eakdown 
of glycogen, ispresent in small amounts in normal 
urine. Greatly increased excretion of the oligosaccharide 
was also observed in several cases with glycogen- 
storage disease type III (9.4-45.2 mg/24 h urine) 
[20]. Since muscular dystrophy is a predominant 
symptom in Pompe's disease it was decided to investi- 
gate some individuals with muscular dystrophies of 
different etiology. A moderately increased excretion 
was found in two patients with Duchenne muscular 
dystrophy and in three patients with unclassified 
muscular disease [20]. This investigation has now been 
extended to include 20 Japanese patients of different 
ages with Duchenne muscular dystrophy of varying 
severity. 
2. Experimental 
Urine samples (24 h) were collected from each of 
the patients tudied. The urines were freeze-dried and 
transported to Sweden where they were reconstituted 
and passed through amixed-bed ion-exchange r sin. 
To 1/lOth of the desalted 24 h urine portions 200/ag 
isomaltotetraose (IM4) were added as an internal 
standard and the sample was reduced and methylated. 
The permethylated oligosaccharides were analyzed 
by gas-liquid chromatography-mass spectrometry 
(GLC-MS). Details concerning this procedure have 
been published in [20]. The identification was based 
on identical retention time and mass spectrum as 
compared with those of an authentic ompound. 
Quantitation of individual oligosaccharides was done 
by comparing the GLC-peak areas with those of the 
internal standard. 
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3. Results and discussion 
Figure 1 shows a typical GLC-tracing obtained 
from subject SH. The dietary-dependent B-trisaccharide 
(B-tri) and B-pentasaccharide (B-penta) [18] demon- 
strate the subject SH is a B-secretor. The tetra- 
saccharide r gion is dominated by 3-sialyllactose (SL), 
(Glc)4 and the internal standard (IM4). 
Apart from the regularly increased level of (Glc)4, 
no other abnormalities were observed in these patterns. 
The excretion rate of (Glc)4 in the 20 patients is 
given in table 1. The mean excretion rate was 
4.9 mg/24 h and the range 3.3-12.0 rag/24 h, which 
in all cases is above normal. No certain correlation to 
age, ABO-blood group or severity of the disease was 
observed. The highest value (12 rag) was seen in a 
patient with relatively mild symptoms (severity 
level 4), whereas the most severe cases tudied 
(severity level 7) had excretion rates lower than the 
mean value for the whole group. 
One can only speculate about the origin of (Glc)4 
in these patients, but it seems likely that in analogy 
with muscular enzymes, glycogen is leaking out from 
muscle cells to a higher extent in the patients than in 
normals. Patients with the largest remaining muscular 
mass would then be expected to have the highest 
excretion levels. The glycogen which is released to the 
circulation is then degraded by serum and/or urine 
amylase to give this 'limit' tetrasaccharide. The amylase 
action on glycogen has been demonstrated in vitro 
and under certain conditions (Glc)4 can be formed 
[21 ]. The increased level of (Glc)4 is most likely 
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Fig.1. GLC-tracing of oligosaccharides, a  their permethylated alditols, in the urine of subject SH. The separation was performed 
on a Perkin-Elmer 3920 gas chromatograph fitted with a glass capillary column (25 m X 0.25 mm) wall-coated with SE-30 
(LKB-Produkter, Sweden) and a flame ionisation detector. A temperature program of 4°C/min from 180-330°C and then iso- 
thermal run at 330°C were employed. The injection was split with an all-glass plitter so that 10% of the injection (1 t~l) was 
introduced onto the column. For abbreviations see text. At the point indicated : ×4, detector sensitivity was increased by a 
factor of 4. 
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Table 1 
Excretion rate of (Glc)~ in 20 normals and in 20 patients with Duchenne 
muscular dystrophy 
Subject Age ABO-blood Severity mg (Glc)4/ 
(years) group level a 24 h urine 
controls 5-20 n.d. Mean = 1.0 
(n = 20) Range = 0.1-2.5 
TF 9 B 6 3.5 
HY 9 B 2 5.6 
YI 9 O 4 7.3 
MY 9 O 5 5.2 
KK 10 A 6 6.6 
KM 11 AB 4 5.4 
NH 12 B 5 4.8 
MT 12 B 6 3.5 
YN 13 O 6 3.3 
MH 13 O 6 4.1 
K K 13 A 6 8.4 
MM 14 A 4 12.0 
YH 14 O 7 4.8 
HK 15 B 6 6.4 
KN 15 A 6 4.2 
KM 15 B 6 4.4 
KY 17 O 7 4.4 
YK 17 O 7 3.4 
SH 18 B 6 6.9 
TO 20 O 6 4.2 
Mean = 4.9 
Range = 3.3-12.0 
a Severity levels are defined as follows: 
1. Can walk and climb up stairs without any help 
2. Can walk, but cannot climb up 
3. Can walk only on flat ground 
4. Can walk, but cannot stand up from a chair 
5. Cannot walk but can move on all fours 
6. Cannot move on all fours, but can crawl on knees 
7. Cannot crawl, but can sit 
8. Stays in bed all the time 
secondary to a generalized membrane defect,  but o f  
course it cannot be ruled out that it is reflecting some 
unknown disturbance in the glycogen metabol ism in 
these patients. 
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